Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Acute Myeloid Leukemia Treatment Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Acute Myeloid Leukemia Market Size @ Acute Myeloid Leukemia Market Outlook- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Myeloid Leukemia Market Report
• In May 2025, Vor Biopharma announced a Phase 1/2 study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
• In May 2025, M.D. Anderson Cancer Center conducted a study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute myeloid leukemia (AML) or those with a mixed phenotype acute leukemia with a myeloid phenotype (MPAL).
• In the 7MM, the US accounted for the highest number of Acute Myeloid Leukemia Incidence Cases i.e., approximately 21,300 cases in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of cases of Acute Myeloid Leukemia, whereas Spain occupied the bottom of the ladder.
• As per DelveInsight's estimates, it has been observed that Acute Myeloid Leukemia is slightly more common in males (~52%) than females (~48%).
• The leading Acute Myeloid Leukemia Companies such as Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca/Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen, Inc., AGC Biologics S.p.A., Precigen, Inc., Novartis Pharmaceuticals, Xencor, Inc./Novartis, and Celgene/Bristol Myers Squibb and others.
• Promising Acute Myeloid Leukemia Pipeline Therapies such as Gemtuzumab ozogamicin, Liposomal Daunorubicin, Mitoxantrone, Treosulfan, Clofarabine, Treosulfan, Bortezomib and others.

Stay ahead in the Acute Myeloid Leukemia Treatment Market with DelveInsight's Strategic Report @ Acute Myeloid Leukemia Market Outlook- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Myeloid Leukemia Epidemiology Segmentation in the 7MM
• Total Acute Myeloid Leukemia Incidence cases
• Acute Myeloid Leukemia Gender-specific cases
• Acute Myeloid Leukemia Age-specific cases
• Acute Myeloid Leukemia Genetic mutations
• Acute Myeloid Leukemia Line-wise Treated Pool

Download the report to understand which factors are driving Acute Myeloid Leukemia Epidemiology trends @ Acute Myeloid Leukemia Prevalence- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Myeloid Leukemia Marketed Drugs
• VANFLYTA (quizartinib): Daiichi Sankyo
Quizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML. In July 2023, the US FDA approved VANFLYTA (quizartinib), with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly Acute Myeloid Leukemia diagnosed that is FLT3 internal tandem duplication (ITD)-positive. Later in September, the drug got approval in Europe for the same patient segment. Quizartinib also is approved in Japan for FLT3-ITD mutation positive AML, and as a monotherapy for relapsed/refractory AML that is FLT3-ITD positive. The quizartinib clinical development program includes a Phase I/II trial in pediatric and young adult patients with relapsed/refractory FLT3-ITD positive AML in Europe and North America and several Phase I/II combination studies as part of a strategic collaboration with the University of Texas MD Anderson Cancer Center.

• ONUREG (azacitidine): Celgene/Bristol Myers Squibb
ONUREG is a nucleoside metabolic inhibitor, and its main Acute Myeloid Leukemia mechanism of action is the hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. The drug received FDA approval in September 2020, for continued treatment of adult patients with AML who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and cannot complete intensive curative therapy. It is the first oral azacitidine product and FDA-approved therapy for continued AML therapy for patients in remission. Later in June 2021, the drug got approved in Europe as well as frontline oral maintenance therapy for adults with AML.

Acute Myeloid Leukemia Emerging Drugs
• Crenolanib: Arog Pharmaceuticals
Crenolanib is a small molecule investigational drug candidate developed by Arog Pharmaceuticals. It is a potent small molecule inhibitor of wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFRα/β (Platelet-Derived Growth Factor Receptor). The drug has been granted ODD and FTD by the US FDA. Crenolanib combined with chemotherapy is currently being studied in two Phase III clinical trials for patients with newly diagnosed AML (NCT03258931) and R/R AML (NCT03250338). Results from a completed Phase II study in newly diagnosed acute myeloid leukemia patients with FLT3 mutations were presented at the ASCO 2024 annual meeting, where crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML resulted in high rate of deep responses and long-term survival with acceptable toxicity.

• SLS009: SELLAS Life Sciences
SLS009 is a potential first- and best-in-class, highly selective, differentiated small molecule CDK9 inhibitor. Compared with other CDK9 inhibitors, SLS009 has reduced toxicity and increased potency. In patients with AML, data has shown SLS009 to demonstrate a high response rate, specifically among those with unfavorable prognostic factors like an ASXL1 mutation. Recently, in July 2024, the FDA granted SLS009 a rare pediatric disease designation (RPDD) for the treatment of pediatric patients AML. Previously, the drug has also been granted an orphan drug designation for the treatment of relapsed/refractory AML, and in January 2024, a fast track designation was granted by the FDA to SLS009 for this same indication.

To learn more about Acute Myeloid Leukemia treatment guidelines, visit @ Acute Myeloid Leukemia Treatment Market Landscape- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Myeloid Leukemia Companies
Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca/Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen, Inc., AGC Biologics S.p.A., Precigen, Inc., Novartis Pharmaceuticals, Xencor, Inc./Novartis, and Celgene/Bristol Myers Squibb and others.

Acute Myeloid Leukemia Market Outlook
The goal of Acute Myeloid Leukemia treatment is remission and current conventional therapeutic options for AML rely on intensive chemotherapy-based induction and consolidation therapy, together with hematopoietic stem cell transplantation. However, not all patients are eligible for this intensive therapy, which can be both physically and mentally demanding, and this approach is more frequently used in healthy, younger patients.

Learn more about the FDA-approved drugs for Acute Myeloid Leukemia @ Drugs for Acute Myeloid Leukemia Treatment- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Myeloid Leukemia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Acute Myeloid Leukemia Companies- Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca/Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen, Inc., AGC Biologics S.p.A., Precigen, Inc., Novartis Pharmaceuticals, Xencor, Inc./Novartis, and Celgene/Bristol Myers Squibb and others.
• Acute Myeloid Leukemia Pipeline Therapies- Gemtuzumab ozogamicin, Liposomal Daunorubicin, Mitoxantrone, Treosulfan, Clofarabine, Treosulfan, Bortezomib and others.
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia Market Drivers and Barriers
• Acute Myeloid Leukemia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Acute Myeloid Leukemia Drugs in development @ Acute Myeloid Leukemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Acute Myeloid Leukemia Market Report Introduction
3 Acute Myeloid Leukemia (AML) Market Overview at a Glance
4 Executive Summary of Acute Myeloid Leukemia (AML)
5 Key Events
6 Acute Myeloid Leukemia Market Disease Background and Overview
7 Epidemiology and Patient Population
8 Key Endpoints in Acute Myeloid Leukemia Clinical Trials
9 Acute Myeloid Leukemia Patient Journey
10 Acute Myeloid Leukemia Marketed Therapies
11 Acute Myeloid Leukemia Emerging Therapies
13 Acute Myeloid Leukemia (AML): 7 Major Market Analysis
14 Acute Myeloid Leukemia SWOT Analysis
15 Acute Myeloid Leukemia Unmet Needs
16 Acute Myeloid Leukemia Market Access
17 Acute Myeloid Leukemia KOL Views
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.